R&D Funding & Commercialization

Developing and deploying advanced technologies like CCUS or large-scale gasification requires substantial, long-term R&D investments with uncertain returns, due to technical complexities and regulatory hurdles.

Despite its foundational role, defence spending is often perceived as a necessary cost rather than a productive investment, leading to political pressures for budget cuts during times of peace, potentially impacting long-term R&D and capabilities.

Lengthy and complex approval processes for research projects (e.g., clinical trials) delay time-to-market for innovations and can deter investment in high-risk areas.

Power outages can destroy invaluable biological samples, chemical reagents, and experimental data, leading to significant financial losses and setbacks in research progress.

Significant time and resources are spent on data conversion and mapping, slowing down design iterations, prototyping, and time-to-market for new rolling stock.

Uncertainty in future market needs and regulatory landscapes makes long-term R&D investments more precarious, potentially misallocating resources on products with limited future viability.

Inconsistent data formats and metadata hinder the ability to reproduce experimental results, a cornerstone of scientific rigor, leading to questions about research validity and trust.

The inability to consistently reproduce experimental results undermines scientific credibility, wastes resources, and can lead to flawed policy decisions or product development, eroding public and investor trust.

The challenge of investing in experimental innovations (e.g., automated stores, drone delivery) while maintaining efficient and profitable traditional store operations.

Balancing numerous experimental projects with core product development, requiring sophisticated portfolio management and risk assessment.

Difficulty in measuring the return on investment for new, unproven ad formats or technologies, leading to hesitation in large-scale adoption.

Demonstrating a clear and quantifiable return on investment for long-cycle R&D projects can be difficult, leading to internal pressure to prioritize short-term gains over strategic long-term innovation.

The need for rigorous clinical trials and scientific substantiation for 'reduced risk' claims requires specialized, high-cost R&D infrastructure.